(Q39091696)

English

Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation

scientific article published on 26 September 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

2

object named as

Choung-Soo Kim

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

author name string

Ji-Young Song

1

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Je-Hwan Lee

3

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Se Jin Jang

4

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Sang-wook Lee

5

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Jung Jin Hwang

6

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Chulsoo Lim

7

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Gilnam Lee

8

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Jeongbeob Seo

9

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Suk Young Cho

10

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Jene Choi

11

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

publication date

26 September 2013

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

31

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

1458-1465

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Global cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Personalized medicine in lung cancer: what we need to know.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Gefitinib-resistance is related to BIM expression in non-small cell lung cancer cell lines

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Selumetinib: a promising pharmacologic approach for KRAS-mutant advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Tumour cell survival signalling by the ERK1/2 pathway

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Analysis of the transcriptional program induced by Raf in epithelial cells

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

High-throughput oncogene mutation profiling in human cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Identifiers

10.1007/S10637-013-0030-0

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

release_v3dm3mevqnhsxnccpsaxevtmoy

1 reference

https://api.fatcat.wiki/v0/release/v3dm3mevqnhsxnccpsaxevtmoy

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39091696&oldid=2202534570"